Publication Name	World Journal of Diabetes
Manuscript ID	103685
Country	China

Category	Endocrinology & Metabolism
Manuscript Type	Basic Study
Article Title	Erianin mitigates diabetic cardiomyopathy via AMPK/Nrf2/HO-1 pathway activation
Manuscript Source	Unsolicited Manuscript
All Author List	Jia-Hui Chen, Xiao-Chun Dai, Zi-Jiao Quan and Xin-Yu Liu
Funding Agency and Grant Number
Corresponding Author	Xin-Yu Liu, PhD, Professor, Department of Gerontology, The First Affiliated Hospital of Jinzhou Medical University, No. 2 Section 5, Renmin Street, Guta District, Jinzhou 121012, Liaoning Province, China. lxy20240520@163.com
Key Words	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip	This study investigates the cardioprotective effects of erianin, a natural compound from dendrobium chrysotoxum, in a type 2 diabetic mouse model. Erianin administration significantly reduced myocardial damage and improved metabolic parameters by activating the adenosine monophosphate-activated protein kinase/nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling pathway. These findings suggest that erianin may serve as a potential therapeutic agent to mitigate cardiac injury and inflammation in diabetes, offering new insights into managing diabetic cardiomyopathy.
Citation	Chen JH, Dai XC, Quan ZJ, Liu XY. Erianin mitigates diabetic cardiomyopathy via adenosine monophosphate-activated protein kinase-nuclear factor erythroid 2-related factor 2-heme oxygenase-1 pathway activation. World J Diabetes 2025; In press

Received	2024-12-20 08:31
Peer-Review Started	2024-12-30 01:16
To Make the First Decision
Return for Revision	2025-01-20 08:27
Revised	2025-03-21 03:40
Second Decision	2025-04-10 03:20
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-04-17 09:22
Articles in Press	2025-04-17 09:22
Publication Fee Transferred	2025-03-25 06:48
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	Chen JH, Dai XC, Quan ZJ, Liu XY. Erianin mitigates diabetic cardiomyopathy via adenosine monophosphate-activated protein kinase-nuclear factor erythroid 2-related factor 2-heme oxygenase-1 pathway activation. World J Diabetes 2025; In press
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com